Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Where Angels Fear To Tread: Lessening The Perils Of CRISPR-Based Therapies

CRISPR is in the headlines once again, but for all the wrong reasons. While germline gene editing remains taboo in legitimate research, it is a reminder that there is much to be learned in ensuring the safety of the technique in general. AstraZeneca has developed a new method which it believes will help avoid off-target effects, an executive explains to In Vivo.

Leadership Outlook 2019 Regenerative Medicine

Pharma Wakes Up To Transformative Progress In Hearing Loss Research

The cacophony of noise in the modern world is one factor driving the loss of hearing throughout humankind, a condition that until now has not been thought amenable to pharmacological intervention. But with small-molecule approaches to regenerating cells in the inner ear bearing fruit, biotech and pharmaceutical companies are taking renewed interest in the sector. 

Research and Development Strategies Research & Development Outlook 2019

Neuroscience Is The Next Oncology: Why Biogen Is Doubling Down

While other large biopharma companies are withdrawing from CNS research, Biogen is rare in not only staying in, but doubling down. Executives at the company’s 40th anniversary event in Switzerland explained why.

Leadership Strategy Companies

Early Stage Candidates Carving Out New Routes In Cystic Fibrosis

Scrip spoke to two companies from a fresh wave of innovators that are approaching drug development for cystic fibrosis from a new angle.

Respiratory Research and Development Strategies Rare Diseases

Four Early-Stage Antibacterial Drugs To Watch: Highlights From IDWeek

Promising drugs from Tetraphase, ContraFect, Spero and Entasis get a platform at the Infectious Diseases Society of America’s IDWeek.

Infectious Diseases Clinical Trials Research & Development